Bicarbonate

Bicarbonate

SCHEMBL570968

O=C(O)O.O=C(O)O.O=C(O)O.O=C(O)O.O=C(O)O.O=C(O)O.O=C(O)O.O=C(O)O

nearest known ligand 1.00 ✓ in ChEMBL — recovers established targets

Full drug profile on Sugi Atlas →

Known targets — ChEMBL curated mechanism

GSK3AGSK3BIMPA1

The experimentally established mechanism targets of Bicarbonate. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CA1 P00915 1/20 1.00
CA2 P00918 1/20 1.00
CA9 Q16790 1/20 1.00
FFAR3 O14843 2/20 0.50
ACHE P22303 1/20 0.50
LCK P06239 1/20 0.50
FYN P06241 1/20 0.50
TSHR P16473 4/20 0.40
LMNA P02545 3/20 0.40
LDHA P00338 2/20 0.40
EGLN1 Q9GZT9 2/20 0.40
LDHB P07195 1/20 0.40
SRR Q9GZT4 1/20 0.40
TP53 P04637 1/20 0.40
ALKBH5 Q6P6C2 1/20 0.40
SUCNR1 Q9BXA5 1/20 0.40
EGLN3 Q9H6Z9 1/20 0.40
OR51E2 Q9H255 2/20 0.38
ALDH1A1 P00352 1/20 0.38
TDP1 Q9NUW8 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Bicarbonate SCHEMBL11066368 1.00 CA1 (1.00) CA1CA2CA9FFAR3ACHE
Bicarbonate SCHEMBL1250901 1.00 CA1 (1.00) CA1CA2CA9FFAR3ACHE
Bicarbonate SCHEMBL6478072 1.00 CA1 (1.00) CA1CA2CA9FFAR3ACHE
Bicarbonate SCHEMBL9672524 1.00 CA1 (1.00) CA1CA2CA9FFAR3ACHE
Bicarbonate SCHEMBL7794 1.00
Bicarbonate SCHEMBL8322803 1.00 CA1 (1.00) CA1CA2CA9FFAR3ACHE
Bicarbonate SCHEMBL570721 1.00 CA1 (1.00) CA1CA2CA9FFAR3ACHE
Bicarbonate SCHEMBL15271537 1.00
Bicarbonate SCHEMBL1179 1.00
Bicarbonate SCHEMBL29131670 1.00 CA1 (1.00) CA1CA2CA9FFAR3ACHE

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 18 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-116987092-A Isosorbide-derived polycarbonate monomer compound, and preparation method and application thereof 同济大学 2023-11-03 CN claimed
CN-113122521-B Polypeptides having lipase activity and uses thereof 丰益国际有限公司 2024-05-14 CN disclosed
CN-116987092-A Isosorbide-derived polycarbonate monomer compound, and preparation method and application thereof 同济大学 2023-11-03 CN disclosed
US-20230165867-A1 IMIDAZOLIDINONE DERIVATIVES AND MEDICAL USE THEREOF KANGBAIDA (SICHUAN) BIOTECHNOLOGY CO., LTD. (CN) 2023-06-01 US disclosed
CN-115867272-A Administration of an enterically selective JAK3 inhibitor 施万生物制药研发IP有限责任公司 2023-03-28 CN disclosed
EP-4137491-A1 IMIDAZOLINONE DERIVATIVE AND USE THEREOF IN MEDICINE Chengdu Baiyu Pharmaceutical Co., Ltd. (CN) 2023-02-22 EP disclosed
CN-114315834-A Imidazolidinone derivatives and their use in medicaments 成都百裕制药股份有限公司 2022-04-12 CN disclosed
WO-2021215274-A1 SKIN EXTERNAL AGENT COMPOSITION AND DEODORANT 株式会社 資生堂 (JP) 2021-10-28 WO disclosed
CN-112812460-A Environment-friendly high-flame-retardance sheath material for PVC optical cable 苏州汇博塑化有限公司 2021-05-18 CN disclosed
CN-110066689-B Scale inhibitor for preventing coking of high-pressure hydrogenation heat exchanger of coking gasoline and diesel oil 中海油天津化工研究设计院有限公司 2021-02-23 CN disclosed
CN-110801431-B Construction and application of core-shell type intelligent nano delivery system 山东大学 2020-11-17 CN disclosed
CN-110801431-A Construction and application of core-shell type intelligent nano delivery system 山东大学 2020-02-18 CN disclosed
US-8637492-B2 Molecular transporter compositions comprising dendrimeric oligoguanidine with a tri-functional core that facilitates delivery into cells in vivo GENE TOOLS, LLC (US) 2014-01-28 US disclosed
US-20120035358-A1 Molecular transporter compositions comprising dendrimeric oligoguanidine with a tri-functional core that facilitates delivery into cells in vivo GENE TOOLS, LLC 2012-02-09 US disclosed
US-7935816-B2 Molecular transporter compositions comprising dendrimeric oligoguanidine with a triazine core that facilitate delivery into cells in vivo GENE TOOLS, LLC (US) 2011-05-03 US disclosed
US-20090171075-A1 Molecular transporter compositions comprising dendrimeric oligoguanidine with a triazine core that facilitate delivery into cells in vivo GENE TOOLS, LLC 2009-07-02 US disclosed
US-20090111775-A1 Molecular transporter compositions comprising dendrimeric oligoguanidine with a tri-functional core that facilitates delivery into cells in vivo GENE TOOLS, LLC 2009-04-30 US disclosed
WO-2009055027-A2 MOLECULAR TRANSPORTER COMPOSITIONS COMPRISING DENDRIMERIC OLIGOGUANIDINE WITH A TRI-FUNCTIONAL CORE THAT FACILITATE DELIVERY INTO CELLS IN VIVO LI YONG-FU (US) 2009-04-30 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090111775-A1 Molecular transporter compositions comprising dendrimeric oligoguanidine with a tri-functional core that facilitates delivery into cells in vivo SLC29A2, SLC29A1, SLC2A9 CA1 3443/4885CA2 1207/4885CA9 1290/4885
US-20090171075-A1 Molecular transporter compositions comprising dendrimeric oligoguanidine with a triazine core that facilitate delivery into cells in vivo SLC18A1, SLC75A1, SLC2A1 CA1 3467/4885CA2 1489/4885CA9 2337/4885
US-20230165867-A1 IMIDAZOLIDINONE DERIVATIVES AND MEDICAL USE THEREOF SYMPK, PAICS, CYP2C9 CA1 2510/4885CA2 1922/4885CA9 330/4885
US-20120035358-A1 Molecular transporter compositions comprising dendrimeric oligoguanidine with a tri-functional core that facilitates delivery into cells in vivo SLC29A2, SLC29A1, SLC2A9 CA1 3443/4885CA2 1207/4885CA9 1290/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.